10 results
Tranexamic Acid - Indications and Pharmacology
Pharmacokinetics:
 • MOA: Inhibits plasminogen activation to plasmin & inhibits fibrinolysis
Indications and Pharmacology ... : Urine Common Uses ... fatigue; Increases risk ... #Indications #Pharmacology ... #hematology
Hydroxychloroquine - Risks and Benefits in Lupus
Benefits:
↓ Disease activity, ↓ Flare, ↓ Damage, ↓ Corticosteroid dose,
Hydroxychloroquine - Risks ... Cardiovascular risk ... deficiency [(limited) risk ... Benefits #Lupus #pharmacology ... #sideeffects #rheumatology
Patient risk stratification algorithm for the treatment of cancer-associated thrombosis.

Currently, edoxaban and rivaroxaban are the only
Patient risk stratification ... algorithm for the ... thrombosis; PE = pulmonary ... Malignancy #Cancer #Algorithm ... Anticoagulation #Management #Hematology
TRALI vs TACO - Transfusion Reactions
TRALI:
 • Epidemiology: 0.1% of transfused patientsl
 • Risk factors: Critical
transfused patientsl • Risk ... without other cause ... transfused patients • Risk ... , and CXR with pulmonary ... Transfusion #Reactions #hematology
Polycythemia - Differential Diagnosis Algorithm
Polycythemia itself isn’t a diagnosis. Like many things, it is a condition
Differential Diagnosis Algorithm ... circulation = risk ... Better call hematology ... about secondary causes ... #workup #hematology
Sjogren's Syndrome Overview

Epidemiology:
• F > M: 9:1
• 5-6th Decades (can be any age)

Autoimmune exocrinopathy multisystemic disease
effusion, INC risk ... PE, Pulmonary amyloidosis ... Malignancy Risk ... lubricants • Pharmacologic ... Sjogrens #Syndrome #Rheumatology
Clarkson’s Disease - Capillary leak syndrome
Epidemiology: Roughly 150 published cases, Median age 50 years, No sex
150 published cases ... vascular filling +++ (risk ... of pulmonary edema ... Prevention of at-risk ... timeline #treatment #rheumatology
It is important to recognize Acute Decompensated Heart Failure (ADHF) as more than just simply a
with presence of pulmonary ... the determined cause ... #differential #algorithm ... #management #cardiology ... icu #clinical #pharmacology
Essential Thrombocythemia (ET)
ET is a chronic myeloproliferative neoplasm. Most cases are related to mutations that affect
• Treatment algorithms ... appropriate only for low risk ... patients with no CV risk ... Thrombocythemia #ET #hematology ... diagnosis #management #hematology
Myelodysplastic syndromes current treatment algorithm 2018.

From Blood Cancer Journal, Published 24 May 2018

Myelodysplastic syndromes (MDS) are
instability with a risk ... and are also at risk ... symptoms and the risk ... have an elevated risk ... #algorithm #hematology